Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction

X
Trial Profile

A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Ramipril; Valsartan
  • Indications Heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms PARADISE-MI
  • Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals
  • Most Recent Events

    • 13 Nov 2023 Results assessing the incidence, risk factors and subsequent mortality after high-risk acute myocardial infarction and comparing the effects of sacubitril/valsartan with the ACE inhibitor ramipril across heart failure (HF) risk categories, presented at the American Heart Association Scientific Sessions 2023.
    • 13 Nov 2023 Results of Subgroup Analysis exploring the safety and tolerability of sacubitril/valsartan versus ramipril when initiated in AMI in the IP, DD or OP care setting, presented at the American Heart Association Scientific Sessions 2023
    • 13 Nov 2023 Results assessing Prognostic Importance of Serial NT-proBNP Measurements Following High-Risk Mi presented at the American Heart Association Scientific Sessions 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top